

A Truncated AdeS Kinase Protein Generated by IS*Aba1* Insertion Correlates with Tigecycline Resistance in *Acinetobacter baumannii*

Jun-Ren Sun^{1,2}, Cheng-Lih Perng^{2,4}, Ming-Chin Chan³, Yuji Morita⁵, Jung-Chung Lin⁶, Chih-Mao Su⁷, Wei-Yao Wang^{1,8}, Tein-Yao Chang^{1,2}, Tzong-Shi Chiueh^{1,2*}

1 Graduate Institute of Medical Science, National Defense Medical Center, Taipei, Taiwan, **2** Division of Clinical Pathology, Department of Pathology, Tri-Service General Hospital, Taipei, Taiwan, **3** Infection Control Office, Tri-Service General Hospital, Taipei, Taiwan, **4** Graduate Institute of Pathology, National Defense Medical Center, Taipei, Taiwan, **5** Department of Microbiology, School of Pharmacy, Aichi Gakuin University, Nagoya, Aichi, Japan, **6** Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Tri-Service-General Hospital, Taipei, Taiwan, **7** Department of Microbiology and Immunology, National Defense Medical Center, Taipei, Taiwan, **8** Division of Infectious Disease, Fong-Yuan Hospital, Taichung, Taiwan

Abstract

Over-expression of AdeABC efflux pump stimulated continuously by the mutated AdeRS two component system has been found to result in antimicrobial resistance, even tigecycline (TGC) resistance, in multidrug-resistant *Acinetobacter baumannii* (MRAB). Although the insertion sequence, IS*Aba1*, contributes to one of the AdeRS mutations, the detail mechanism remains unclear. In the present study we collected 130 TGC-resistant isolates from 317 carbapenem resistant MRAB (MRAB-C) isolates, and 38 of them were characterized with IS*Aba1* insertion in the *adeS* gene. The relationship between the expression of AdeABC efflux pump and TGC resistant was verified indirectly by successfully reducing TGC resistance with NMP, an efflux pump inhibitor. Further analysis showed that the remaining gene following the IS*Aba1* insertion was still transcribed to generate a truncated AdeS protein by the *Pout* promoter on IS*Aba1* instead of frame shift or pre-termination. Through introducing a series of recombinant *adeRS* constructs into a *adeRS* knockout strain, we demonstrated the truncated AdeS protein was constitutively produced and stimulating the expression of AdeABC efflux pump via interaction with AdeR. Our findings suggest a mechanism of antimicrobial resistance induced by an aberrant cytoplasmic sensor derived from an insertion element.

Citation: Sun J-R, Perng C-L, Chan M-C, Morita Y, Lin J-C, et al. (2012) A Truncated AdeS Kinase Protein Generated by IS*Aba1* Insertion Correlates with Tigecycline Resistance in *Acinetobacter baumannii*. PLoS ONE 7(11): e49534. doi:10.1371/journal.pone.0049534

Editor: Mark Alexander Webber, University of Birmingham, United Kingdom

Received: May 21, 2012; **Accepted:** October 10, 2012; **Published:** November 14, 2012

Copyright: © 2012 Sun et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study was supported by grants TSGH-C101-128 from the Tri-Service General Hospital, Taiwan, Republic of China. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: drche0523@gmail.com

Introduction

Acinetobacter baumannii, a Gram-negative coccobacillus usually found in soil and water, has emerged as a highly problematic nosocomial pathogen [1]. *A. baumannii* constitutes a major public health problem due to its intrinsic resilience to numerous drugs and its ability to readily acquire new resistance determinants [2,3]. Multidrug-resistant *A. baumannii* resistant to carbapenem (MRAB-C) has been increasingly reported worldwide, which raises serious concern about the limited antimicrobial treatment options [4].

Multidrug efflux pumps belonging to the resistance-nodulation-cell division (RND) family have been shown to play an important role in the antimicrobial resistance of *A. baumannii* [3,5]. To date, three different RND pumps have been identified in *A. baumannii*, namely AdeABC, AdeIJK and AdeFGH. AdeABC efflux pump is the first characterized RND system in *A. baumannii* [3]. Overexpression of the AdeABC efflux pump has been shown to pump out aminoglycosides, beta-lactam, fluoroquinolone, tetracycline, macrolide, chloramphenicol, trimethoprim, and even tigecycline (TGC). TGC is the first member of the glycylcycline and is considered a bacteriostatic drug with high efficacy in treating a

broad range of antibiotic-resistant bacteria [4,6]. Previous studies have shown that TGC has poor activities against MRAB-C due to over-expression of the AdeABC efflux pump system [3,7,8,9,10,11]. The AdeIJK efflux pump contributes minimally to acquired resistance due to its toxicity for the host [12]. The third efflux pump, AdeFGH, its overexpression confers high-level resistance to most antibiotics except β -lactam and aminoglycosides [13]. Its overexpression is therefore least expected to result in the multidrug resistance in MRAB-C isolates. The expression of AdeABC efflux pump is tightly regulated by the two-component system which contains a sensor kinase (SK) AdeS and a response regulator (RR) AdeR, encoded by the *adeRS* operon. The *adeRS* operon is located at the upstream of *adeABC* operon and is transcribed in the opposite direction [3,7,14]. The promoters of the *adeABC* operon and the *adeRS* operon were predicted at the region between the two operons [14].

In micro-organisms, the two-component system is a very important signal transduction system for adaptation to drastic and immediate changes in external or internal environmental conditions [15]. This system is usually composed of a RR and a SK. The SK monitor's certain signal is caused by environmental

Table 1. Bacterial strains and plasmids used in this study.

Strains or plasmids	Relevant characteristics	Reference	
<i>E. coli</i> strains	DH5 α	Φ 80d, <i>lacZM15</i> , <i>endA1</i> , <i>recA1</i> , <i>hsdR17</i> (r $^-$, m $^+$), supE44, thi-1, <i>gyrA96</i> , <i>relA1</i> , F $^-$ (<i>lacZYA-argF</i>)U169	Lab stock
<i>Acinetobacter baumannii</i> strains	ATCC 15151	<i>A. baumannii</i> reference strain	ATCC
	ABmut02	Derived from BCRC15884. <i>adeRS</i> mutant obtained by plasmid insertion. KanR, AmpR	This study
	AB039	clinical MDR strain, TGC MIC = 2 mg/L, <i>adeRS</i> without IS element insertion	
	AB090	clinical MDR strain, TGC MIC = 1 mg/L, <i>adeS</i> mutant obtained by IS <i>aba1</i> insertion	This study
	AB096	clinical MDR strain, TGC MIC = 16 mg/L, <i>adeRS</i> without IS element insertion	
	AB260	clinical MDR strain, TGC MIC = 1 mg/L, <i>adeS</i> mutant obtained by IS <i>aba1</i> insertion	This study
	AB293	clinical MDR strain, TGC MIC = 16 mg/L, <i>adeS</i> mutant obtained by IS <i>aba1</i> insertion	This study
	AB392	clinical MDR strain, TGC MIC \leq 0.5 mg/L, <i>adeR</i> mutant obtained by IS <i>aba125</i> insertion	This study
Plasmids	pMU125	<i>E. coli</i> - <i>Acinetobacter</i> shuttle plasmid with <i>A. baumannii</i> replication origin	[37]
	pCR2.1-Topo	Suicide plasmid for <i>A. baumannii</i> . KanR, AmpR	Invitrogen
	pCR2.1- <i>adeR</i> int	pCR2.1-Topo containing a 513-bp internal fragment of the <i>adeR</i> . KanR, AmpR	This study
	pYM102	mini-CTX:: <i>lacI^f-P₁₇-lacZ</i>	[40]
	pS01	<i>E. coli</i> - <i>Acinetobacter</i> shuttle plasmid with <i>A. baumannii</i> replication origin; mini-CTX:: <i>lacIq-PT7-lacZ</i>	This study
	pRS- <i>adeRS</i> (wt)	Derived from pRS, mini-CTX:: <i>adeRS-Pade-lacZ</i> (<i>adeRS</i> from ATCC 15151)	This study
	pRS- <i>adeRS</i> (AB090)	Derived from pRS, mini-CTX:: <i>adeRS-Pade-lacZ</i> (<i>adeRS</i> from AB260)	This study
	pRS- <i>adeRS</i> (AB293)	Derived from pRS, mini-CTX:: <i>adeRS-Pade-lacZ</i> (<i>adeRS</i> from AB293)	This study
	pRS- <i>adeR</i> (wt)	Derived from pRS, mini-CTX:: <i>adeR-Pade-lacZ</i> (<i>adeR</i> from ATCC 15151)	This study
	pRS- <i>adeR</i> (AB260)	Derived from pRS, mini-CTX:: <i>adeR-Pade-lacZ</i> (<i>adeR</i> from AB260)	This study
	pRS- <i>adeR</i> (AB293)	Derived from pRS, mini-CTX:: <i>adeR-Pade-lacZ</i> (<i>adeR</i> from AB293)	This study
	pRS-Pade-Pout-truncated <i>adeS</i>	Derived from pRS- <i>adeRS</i> (AB293), <i>SphI</i> digested and self-ligation. mini-CTX:: <i>truncated adeS-Pout-Pade-lacZ</i>	This study
	pRS-Pout-truncated <i>adeS</i>	Derived from pRS, mini-CTX:: <i>truncated adeS -Pout-lacZ</i> (soluble <i>adeS</i> from AB293)	This study
	pRS-Pout-truncated <i>adeS</i> (SDM)	Derived from pRS_Pout-truncated <i>adeS</i> , mutated at the start code ATG to AAG by site-directed mutagenesis	This study

doi:10.1371/journal.pone.0049534.t001

changes. Signal bound to sensor domains of SK normally results in inducing an ATP dependent auto-phosphorylation of the histidine kinase domain in the catalytic core of the enzyme and transmitting the information to RR via a phosphoryl-transfer reaction to aspartate residue in RR. The RR is shifted to its active state by the phosphate group received and is directly bound to the promoter region of its target genes as a transcriptional regulator [16]. The typical type of SK is a homodimeric integral membrane protein in which the sensor domain, direct detection of extracellular signals, is formed by an extracellular loop contained between two membrane-spanning segments. The transmitter domain contains a histidine kinase A (HisKA) domain, and an ATP-binding domain follows the last transmembrane segment at the C-terminus and is localized within the cytoplasm [15]. However, some SKs which deviate from the typical type of SK model with their sensor domains within the membrane or fully cytoplasmic are found in bacteria, fungi, and plant [16]. The cytoplasmic SK is a protein located in the cytoplasm comprising a sensor domain and transmitter domain, without a transmembrane domain [16,17,18,19,20].

Several families of Insertion sequence (IS) in *A. baumannii* have been associated with acquired antimicrobial resistance mechanisms [21]. Many IS elements are related to antibiotic resistance through two mechanisms. Some of the IS elements contain promoters which can enhance the expression of their downstream antibiotic resistance genes [22]. IS*Aba1* has been found in upstream of *ampC*, *bla_{OXA-23}*, *bla_{OXA-27}*, *bla_{OXA-51}* and *suII* antibiotic resistance genes [22,23,24,25,26,27,28,29,30]. Other elements, such as IS*Aba2*, IS*Aba3*, and IS*Aba4* contain preceding promoters that enhance the expression of carbapenem resistant genes, *bla_{OXA-58}* and the *bla_{OXA-23}* genes [31,32,33]. Moreover, the IS element may be inserted into and may disrupt the coding region of an outer membrane protein gene. The loss of the outer membrane protein results in resistance by blocking the input of antibiotics. Previous research described that an insertion mutation within the *carO* outer membrane protein gene by the IS*Aba1*, IS*Aba125*, or IS*Aba825* element was associated with carbapenem resistant [22,30,34].

Previous studies found that IS*Aba1* insertion mutation within the *adeS* gene can enhance overexpression of the AdeABC efflux pump

system and cause TGC resistant [9]. Excessive transcription of *adeABC* operon was triggered due to a strong promoter in *ISAbal* or the disruption of the AdeS protein. However, the detail mechanism regarding how the *ISAbal* element controls the AdeABC efflux pump over-expression remains unknown. In the present study, we investigated the prevalence, genotype, AdeABC efflux pump expression and TGC resistance pattern of MRAB-C clinical isolates in which *adeRS* operon was uniquely destroyed by insertion of an IS element. Further, we identified a truncated cytoplasmic AdeS encoded by an extra operon driven by the promoter within the *ISAbal* element. The truncated AdeS protein was then responsible for enhancing AdeABC efflux pump over-expression.

Materials and Methods

Bacterial strains, growth media and plasmids

A total of 317 distinct clinical isolates of MRAB-C were collected in this study at Tri-Service General Hospital from 2008 to 2010. The bacterial strains and plasmids used in this study are listed in Table 1. Bacteria were grown routinely in Luria–Bertani (LB) broth (BD Difco, Franklin Lakes, NJ) at 37°C with shaking. Plasmids were maintained and selected in *E. coli* and *A. baumannii* hosts using a medium supplemented with the following antibiotics: ampicillin (Sigma-Aldrich, Poole, UK) (100 mg/L); kanamycin (Sigma-Aldrich) (50 mg/L); and tetracycline (Sigma-Aldrich) (5 mg/L).

Antimicrobial susceptibility tests

All bacterial cultures were prepared on the day of antimicrobial susceptibility testing. The U.S. Food and Drug Administration (FDA) recommended tigecycline (TGC) susceptibility breakpoints for *Enterobacteriaceae* (susceptible MIC, ≤ 2 g/L; intermediate MIC, >2 and <8 g/L; resistant MIC, ≥ 8 g/L) were used as MIC interpretation criteria. TGC (Wyeth, Madison, NJ) powder was obtained from commercial sources and was prepared in a solution with sterilized water, and the solution was then frozen in aliquots at -80°C . TGC MICs were initially determined by the E-test (AB Biodisk, Solna, Sweden) and confirmed by the agar dilution test using Mueller–Hinton II agar (BD Difco). Susceptibility tests of other antimicrobials were performed by the VITEK-2 system (bioMérieux, Marcy l’Étoile, France). All strains were tested for susceptibility to the following antibiotics: ampicillin, cefazolin, gentamicin, amikacin, ampicillin/sulbactam, piperacillin/tazobactam, trimethoprim/sulfamethoxazole, ceftazidime, ceftriaxone, imipenem, ciprofloxacin, cefepime, nitrofurantoin, tigecycline and levofloxacin. To verify the over-expression of efflux pump, we prepared Mueller–Hinton (M-H) agar plates with and without adding the efflux pump inhibitor 1-(1-naphthylmethyl)-piperazine (NMP) (Sigma-Aldrich). The final concentration of NMP in the M-H agar was 64 mg/L. The MICs of TGC in the presence or absence of NMP were determined by the E-test described above.

DNA manipulations

Genomic DNA was isolated using the protocol suggested in the literature [35]. Plasmid DNA was isolated by the Viogene plasmid DNA extraction miniprep system (Viogene biotek corporation, Taiwan). DNA concentration measurements were performed with a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Inc., Wilmington, DE, USA). Standard PCR amplifications were performed with the DyNAzyme DNA polymerase (Finnzymes, Espoo, Finland). When necessary, high fidelity and blunt-ended PCR products were amplified with Phusion DNA Polymerase (Finnzymes). PCR products were purified with

Viogene Gel and PCR Clean-Up kit (Viogene). Oligonucleotide was synthesized by Genomics BioScience and Technologies, Inc. (Taiwan). All oligonucleotides used in the study are listed in Table 2. Thermal cycle reactions were performed using the 9700 GeneAmp thermocycler (Applied Biosystems, Foster City, CA). Nucleotide sequencing was performed with BigDye Terminator Cycle Sequencing kit (Applied Biosystems) according to the manufacturer’s instructions. Capillary electrophoresis was performed with a 3730XL Genetic Analyzer (Applied Biosystems) and then analyzed by BioEdit software (<http://www.mbio.ncsu.edu/BioEdit/bioedit.html>). Restriction enzymes were purchased from New England Biolabs (New England Biolabs, Beverly, MA) and used according to the manufacturer’s recommendation. Fast-Link DNA Ligation Kit was purchased from Epicentre (Epicentre, Madison, Wisconsin) and used according to the manufacturer’s recommendation. Competent cells were prepared and transformed by electroporation as previously described [36]. The sequence was analyzed with the NCBI BlastX bioinformatic tool (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>) and the NCBI open reading frame (ORF) finder (<http://www.ncbi.nlm.nih.gov/projects/gorf/>).

Quantitative real-time PCR

To detect the expression of *adeR*, *adeS*, *adeA* and *adeB* gene, quantitative real-time RT-PCR was performed individually for each. Primers for the quantitative real-time were designed using Primer3 software. The efficiency of each primer pair in quantitative real-time PCR has been determined by a 10-fold serial dilution of the template. By plotting the log values of template concentrations on the x-axis and the Ct values on the y-axis, standard linear lines with slopes (m) ranging from -3.58 to -3.27 were obtained. We obtained 95.1~105.0% amplification efficiencies (E_{Amp}) for the primer pairs based on the calculation equation, $E_{\text{Amp}} = 10^{-1/m} - 1$. *A. baumannii* cells were grown aerobically in LB broth until reaching the mid-log phase. DNaseI-treated RNA templates were prepared using an RNeasy kit (QIAGEN Sciences, MD). The concentrations of the RNA were quantified with a spectrophotometer. Reverse transcription was performed using a high-capacity cDNA archive kit (Applied Biosystems) with 200 ng of RNA in a 20 μL reaction mixture containing 1 \times (each) reverse transcription buffer, deoxynucleoside triphosphate mix, and random primers as well as 2.5 U/ml multiscribe reverse transcriptase. Negative-control reactions included equal concentrations of RNA and all reagents while omitting reverse transcriptase. Incubation for 10 min at 25°C followed by 2 h at 37°C was carried out with a GeneAmp PCR System 9700 thermal cycler (Applied Biosystems). Real time PCR was performed with the DyNAmoTM Flash SYBR Green qPCR Kit (Finnzymes) and a 1:10 final dilution of the cDNA product on the ABI PRISM 7500 Real-Time PCR system (Applied Biosystems). Each PCR analysis contained one primer pair. Cycling conditions were as follows: denature at 95°C for 10 min, followed with 40 cycles of denature at 95°C for 15 s and annealing/extension at 56°C for 30 s, and finalized with 1 cycle at 95°C for 30 s and 28°C for 30 s. Following PCR cycling, melting point data were collected and the dissociation curve was examined for each well. The critical threshold cycle (Ct) numbers were determined by Sequence Detection Systems version 2.2.2 (Applied Biosystems). In order to omit efficiency variation among primer pairs, ΔCt and $\Delta\Delta\text{Ct}$ were applied for comparing the gene expression level. The ΔCt for gene expression was calculated against that for the *rhoB* housekeeping gene, and the $\Delta\Delta\text{Ct}$ was calculated against that for the TGC-susceptible control strain (ATCC 15151, wt) as suggested in the literature.

Table 2. Oligonucleotides used in this study.

Primer name	Sequence	Features/purpose	Source
adeRS_1f	ATGTTTGATCATTCTTTTCTTTG	Detection the IS element insertion within the <i>adeRS</i> operon and Sequencing of <i>adeRS</i> operon	[41]
adeRS_1849r	TTAGTTATTCATAGAAATTTTATG		
adeRS_689r	TTAATTAACATTGAAATATG		
adeRS_776f	ATGAAAAGTAAGTTAGGAATTAGTAAG		
ISAbal-F	CATTGGCATTAAACTGAGGAGAAA	with <i>adeRS_1849r</i> primer to confirm the insertion of <i>ISaba1</i> within the <i>adeS</i> operon	This study
ISAbal-R	TTGGAAATGGGGAAAACGAA	with <i>adeRS_1f</i> primer to confirm the insertion of <i>ISaba1</i> within the <i>adeS</i> operon	This study
pWH1266_ori_PstI_F	GCCTGCAGGATCGTAGAAATATCTATGA	Cloning of <i>A. baumannii</i> replication origin from pMU125 with engineered <i>PstI</i> site	This study
pWH1266_ori_PstI_SmaI_R	AACTGCAGACCCGGGGATTAAACATTTTGCCTTG		
AdeA_promoter_f_BamHI	CACGGATCCAACCTAGTGAGTTTTGATGTTCCG	Cloning <i>adeRS</i> operon and promoter <i>ade</i> with engineered <i>SmaI</i> and <i>BamHI</i> site into pRS to form pRS- <i>adeRS</i>	This study
AdeS_r_SmaI	CGCCCCGGGTAGTTATTCATAGAAATTTTATG		
AdeR_r_SmaI	CACCCCCGGTATTAGGCGTCATCTTTACAGC	With <i>AdeA_promoter_f_BamHI</i> primer to clone <i>adeR</i> operon and promoter <i>ade</i> with engineered <i>SmaI</i> and <i>BamHI</i> site into pRS to form pRS- <i>adeR</i>	This study
ISaba1Pout_f_BamHI	CACGGATCCAAGCATGATGAGCGCAAAG	With <i>AdeS_r_SmaI</i> primer to clone soluble <i>adeS</i> operon and <i>ISaba1 Pout</i> with engineered <i>SmaI</i> and <i>BamHI</i> site into pRS to form pRS-Pout-soluble <i>adeS</i>	This study
adeR_6f	TGATCATTCTTTTCTTTGATTGCCAAGA	Cloning the partial sequence of <i>adeR</i> into pCR2.1-Topo to form pTOPO <i>adeR</i>	This study
adeR_514r	CAGTCAGCGTCAGATTAAGCA		
adeA_F	TTGATCGTGCTTCTATTCTCAAG	RT-PCR of <i>adeA</i> gene	
adeA_R	GGCTGCCACTGATATTACGTT		
adeB_F	GGATTATGGCGACAGAAGGA	RT-PCR of <i>adeB</i> gene	
adeB_R	AATACTGCCCAATACCAG		
QPCR_adeRS1661_f	ACCGAGTCCAAGACGAT	RT-PCR of <i>adeS</i> gene	This study
QPCR_adeRS1782_r	CCTTTCAGTGCCACAATA		
QPCR_adeR96_f	AAAACGTGAAGGCATGAGTG	RT-PCR of <i>adeR</i> gene	This study
QPCR_adeR220_r	CTTCCAACCGTTAATTCG		
rpoB_f	TCCGCACGTAAGTAGGAAC	RT-PCR of <i>rpoB</i> gene	
rpoB_r	ATGCCGCTGAAAAGTAAC		
TruncatedAdeS_SDMut_sense	ATAATTTAATGATAAGGCTCAAAGC	change the start code ATG to AAG in soluble <i>adeS</i> by site-directed mutagenesis at pRS-Pout-soluble <i>adeS</i>	This study

doi:10.1371/journal.pone.0049534.t002

Knockout the *adeRS* operon by homologous recombination

Plasmid inserted with the *adeRS* operon of *A. baumannii* was carried out as previously described [36]. Briefly, kanamycin and ampicillin resistant plasmid pCR2.1-Topo, unable to replicate in *A. baumannii*, was used as a suicide vector. An internal fragment (513 bp) of the *adeR* gene was amplified by PCR with *AdeR_6f* and *AdeR_514r* primers (Table 2) from a template of *A. baumannii* ATCC 15151 genomic DNA. The PCR product was cloned into the pCR2.1-Topo vector and electroporated into *E. coli* to yield the pCR2.1-*adeRint* plasmid (Table 1). Recombinant plasmid (100 ng) was then introduced in the kanamycin and ampicillin susceptible *A. baumannii* ATCC 15151 by electroporation [36]. Mutants were selected on LB agar plates containing kanamycin

and ampicillin. Inactivation of the *adeRS* operon by insertion of the plasmid via a single crossover recombination was confirmed by sequencing the amplified PCR products with the *AdeA_promoter_f_BamHI* and *AdeRS_1849r* primer pairs (Table 2).

Construction of the *E. coli*-*Acinetobacter* shuttle vector pS01

The DNA fragment of *A. baumannii* replication origin was obtained by PCR using primers *pWH1266_ori_PstI_F* and *pWH1266_ori_PstI_SmaI_R* (Table 2) in a reaction mixture (50 μ L) containing 1 U of Phusion DNA Polymerase, 0.2 mM of each deoxynucleoside triphosphate, 1 \times PCR buffer, 5 pmol of each primer, 2 mM MgSO₄ and 10 ng of pMU125 DNA as the template [37]. For PCR, the reaction mixture was subjected to an

initial 1 min denaturation step at 98°C, followed by 35 cycles of 10 s at 98°C, 10 s at 55°C, and 30 s at 72°C and a 10 min final elongation at 72°C. The purified PCR product was then cloned into plasmid pYM102 through the *Pst* I site. The resulting construct, pS01, was sequenced to verify the absence of PCR-introduced mutations.

Construction of pRS series for expressing the *adeRS*, *adeR* and Pout-truncated *adeS* genes

The plasmid pS01 was digested with *Sma*I and *Bam*HI for 2 h at 37°C (or 25°C in the case of *Sma*I) to delete its *lacF^l* gene and T7 early gene promoter. The digested plasmids were ligated with the respective gene fragments to generate a series of recombinant pRS clones, including pRS-*adeRS* (wt), pRS-*adeRS* (AB090), pRS-*adeRS* (AB293), pRS-*adeR* (wt), pRS-*adeR* (AB260), pRS-*adeR* (AB293) and pRS-Pout-truncated-*adeS*. The *adeRS* and *adeR* gene fragments of ATCC 15151 and AB260 were amplified by PCR using common forward primer AdeA_promoter_f_ *Bam*HI with reverse primers AdeS_r_ *Sma*I and AdeR_r_ *Sma*I, respectively (Table 2). The Pout-truncated *adeS* gene fragment of AB293 was amplified by PCR using primers IS*Aba*I/Pout_f_ *Bam*HI and AdeS_r_ *Sma*I. Another plasmid pRS-Pade-Pout-truncated *adeS* was obtained by splicing out the DNA fragment between *Pade* and *Pout* of IS*Aba*I in pRS-*adeRS* (AB293) with *Sph*I digestion and re-ligation.

Site Directed Mutagenesis

The site-directed mutagenesis (SDM) protocol was modified from the previous study [38]. We used plasmid pRS-Pout-truncated *adeS* as the template for SDM to disrupt start codon (ATG to AAG). The plasmid was amplified using a mutation bearing primer TruncatedAdeS_SDMut_sense in PCR reaction mixture (25 µL) containing 1 µg template, 1 U of Phusion DNA Polymerase, 0.2 mM of each deoxynucleoside triphosphate, 1× PCR buffer, 5 pmol of SDM primer, 2 mM MgSO₄ and 10% (vol/vol) dimethyl sulfoxide (DMSO). For PCR, the reaction mixture was subjected to an initial 30 sec denaturation step at 98°C, followed by 28 cycles of 10 s at 98°C, 30 s at 50°C, and 4 min at 72°C and a 10-min final elongation at 72°C. The PCR product was further treated with 5 U of *Dpn*I at 37°C for 1 hr. The *Dpn*I-treated PCR product was directly transformed into DH5α competent cells. Transformants were incubated in 5 ml LB medium containing 5 mg/L tetracycline overnight. Tetracycline resistant colonies were isolated and extracted for plasmid content. Mutant start codon in the successfully transformed plasmid was confirmed by DNA sequencing.

Pulsed-field gel electrophoresis

All clinical *A. baumannii* isolates with the IS element in their *adeRS* operon were genotyped by the pulsed-field gel electrophoresis (PFGE). Total DNA was prepared and PFGE was performed as described previously [39]. Endonuclease *Apa*I was used to digest the bacterial DNA, and then restriction fragments were analyzed by PFGE in 1% SeaKem Gold agarose gels (Cambrex Bio Science, Rockland, ME, USA) in 0.5× TBE buffer (45 mM Tris, 45 mM boric acid, 1.0 mM EDTA, pH 8.0) using a Bio-Rad CHEF-Mapper apparatus (Bio-Rad Laboratories, Hercules, CA). Gels were stained with ethidium bromide and photographed under ultraviolet light. Dendrograms showing percentage similarity were prepared with the Molecular Analyst Fingerprinting, Fingerprinting Plus and Fingerprinting DST Software (Bio-Rad Laboratories) and were compared using the UPGMA clustering method as proposed in previous studies [10,39]. Isolates with similarity over 90% were considered to be identical; isolates with

below 70% similarity (>3 band difference) were considered to be non-clonally related, using previously described criteria [39].

Measurement of β-galactosidase activity

β-galactosidase activity assay was modified from the method described by Miller (1992) [40]. Briefly, 0.5 mL bacterial suspension of 37°C overnight culture was placed on ice for 20 min, and then harvested by centrifugation at 8000×g for 5 min at 4°C. The pellets were re-suspended in 0.5 mL of Z buffer (60 mM Na₂HPO₄·7H₂O, 40 mM NaH₂PO₄·H₂O, 10 mM KCl, 1 mM MgSO₄·7H₂O, 50 mM β-mercaptoethanol, pH 7.0) and the OD₆₀₀ of the resuspended cells was measured (blank against Z buffer). To lysis the cells, 0.1 mL of the cell suspension was mixed with 0.4 mL of Z buffer, 50 µL of chloroform, and 25 µL of 0.1% Sodium dodecyl sulfate, vortexed for 10 sec, and incubated at 28°C. At a time point defined as zero, 0.1 mL of ONPG (o-nitrophenyl-β-D-galactopyranoside) (Sigma-Aldrich) (4 g/L) was added to the lysed cell suspension. The reaction was stopped by adding 0.25 mL of 1 M Na₂CO₃ at a time defined as T and the OD was then measured at 420 nm and 550 nm using a Synergy HT multi-mode microplate reader (BioTek Instruments, Winooski, VT). The activity of β-galactosidase was calculated using the following equation: $1000 \times [OD_{420} - (1.75 \times OD_{550})] / [(T \text{ (min)} \times 0.2 \text{ (mL)} \times OD_{600})]$, expressed in Miller units.

Nucleotide sequence accession number


The 3038 -bp DNA sequences of the *adeRS* operon of AB260 and AB293 corresponding to the IS*Aba*I-interrupted *adeS* gene were submitted to the GenBank database as accession number JQ690823 and Q690824, respectively. The 2941-bp DNA sequence of the *adeRS* operon of AB392 corresponding to the IS*Aba*I25-interrupted *adeR* gene was submitted to the GenBank database as accession number JQ690825.

Results

Compatible antibiotics susceptibility with PFGE genotyping results in MRAB-C isolates

Antimicrobial susceptibility testing revealed that the 317 clinical MRAB-C isolates were resistant to all antibiotics tested in the Vitek-2 system. Using the FDA criteria for the agar dilution method, 130 (41%), 131 (41.3%), and 56 (17.7%) isolates were resistant, intermediate, and susceptible to TGC, respectively (Figure 1A). The full length of *adeRS* operon in each MRAB-C isolate was expected to be consistent in size (1.8 kb) after PCR amplification. However, the PCR products from 41 isolates were about 3.0 kb, which indicates additional DNA sequences within the *adeRS* operon. Among the 41 isolates, 38 (92.7%) isolates were resistant and 3 (7.3%) were susceptible to TGC. In a previous study, we demonstrated the expression of AdeABC efflux pump is significantly correlated with MIC of TGC in clinical isolates during the period [10]. To verify the effect of AdeABC efflux pump on TGC resistance, all MRAB-C isolates were tested for their MIC of TGC in the presence of NMP, an efflux pump inhibitor (Figure 1B). On plates with NMP, their E-test MIC (0.5–4 mg/L) of TGC showed 2–8 folds lower values than those without NMP (8–16 mg/L). TGC resistance was therefore related to AdeABC efflux pump overexpression in these isolates. After comparing the genotype patterns by pulsed field gel electrophoresis (PFGE) with *Apa*I-digestion, the 41 isolates were classified into 3 clusters and 3 sporadic clones based on PFGE criteria (Figure 2). The genotypic grouping result was compatible with phenotypes of TGC susceptibility. Two major clusters (AB354-AB338 and AB92-AB335 in Figure 2) and one minor cluster (AB341 and AB351)

A



B




Figure 1. Tigecycline MIC profile of the clinical *A. baumannii* isolates. (A) Distribution of tigecycline MIC of the clinical *A. baumannii* isolates with (black bar) and without (grey bar) insertion of additional DNA in their *adeRS* operon (B) MIC to tigecycline alone (grey bar) and to tigecycline/NMP combination (black bar) for the 41 clinical *A. baumannii* isolates with insertion of additional DNA in their *adeRS* operon. doi:10.1371/journal.pone.0049534.g001

contained 38 (92.7%, 38/41) of all the MRAB-C isolates that were all TGC resistant. The remaining 3 sporadic clones (AB90, AB260 and AB392) were TGC susceptible.

IS elements within the *adeRS* operon found by sequencing analysis

To determine the additional DNA insertion in *adeRS* operon, direct sequencing of *adeRS* operon PCR products showed the




Figure 2. Pulsed-field gel electrophoresis (PFGE) for *ApaI* of 41 *A. baumannii* isolates with insertion of additional DNA in their *adeRS* operon. Dendrogram was generated by UPGMA clustering.
doi:10.1371/journal.pone.0049534.g002

presence of the *IS_{Aba125}* element within the *adeR* gene in AB392 isolates and the *IS_{Aba1}* element within the *adeS* gene in the remaining 40 strains (Figure 3A). The *IS_{Aba125}* element was 1,087-bp in length. It contained a 969-bp open reading frame (ORF) encoding a putative transposase, and was bounded by 15-bp inverted repeat sequences which are common to members of the *IS₃₀* group. Two 9-bp individual sequences (GGCGAATTC and TACTCTGCC) flanked the *IS_{Aba125}* at the predicted insertion site in *adeR* gene of AB392. The presence of *IS_{Aba125}* mediated disruptive events on the *adeR* gene in AB392, resulting in the loss function of *adeR*, and maybe affecting the expression of the AdeABC efflux pump system. The *IS_{Aba1}* element was 1180-bp in length, containing two consecutive and overlapping ORFs, 567-bp ORF1 and 535-bp ORF2. It was therefore likely that a frame-shift is necessary to generate a unique protein as functional transposase. The *IS_{Aba1}* was bounded by 15-bp inverted repeat sequences which are common to members of the *IS₄* family (Figure 3A). A 9-bp duplication (ATAATTTTA) flanked *IS_{Aba1}* at the predicted insertion site in *adeS* gene of the other isolates. The presence of *IS_{Aba1}* mediated disruptive events on the *adeS* gene, resulting in the loss function of *adeS* gene, and maybe affecting the expression of the AdeABC efflux pump system. However, we noted the most striking difference in the distribution of TGC MIC in the isolates. Only 2 strains (AB090 and AB260) were TGC susceptible and the remaining 38 isolates were TGC resistant. Hence, it was necessary to investigate whether the phenomenon was caused by DNA mutation in the promoter region or in *adeRS* operon. Nucleotide sequences of the promoter region and the *adeRS* operon with

IS_{Aba1} insertion were analyzed by multiple sequence alignment. DNA sequences of the promoter region and the destroyed *adeS* gene were identical among the 38 TGC resistant isolates. However, two point mutations (Met197Ile) and (Ser200Cys) in *adeR* gene were identified in all isolates, except for the two TGC sensitive isolates.


Transcript analysis of *adeABC* operon and *adeRS* operon

As the synergistic effect of NMP on TGC susceptibility described above, the TGC resistance may be associated with up-regulation of the AdeABC efflux pump in those isolates with their *adeS* gene destroyed by *IS_{Aba1}*. We investigated the transcription activity of *adeRS* operon and *adeABC* operon in representative isolates with various TGC MICs using quantitative real-time RT-PCR (Table 3). The two isolates (AB039 and AB096) were discussed in our previous research [10,41,42]. They both have higher MIC of TGC than strain ATCC 15151. The MICs of TGC were 2 mg/L and 16 mg/L for AB39 and AB96, respectively. Although the detail mechanism was not explored, we have demonstrated the higher MIC is proportionally correlated with the *adeB* expression level. We used these two strains simply to show the consistency of our experiment. We were still not able to identify the exact cause for their difference. In this manuscript, nonetheless, we focused on the group of isolates with an insertion element.


To quantify the *adeRS* operon expression in strains with various IS element insertion, the first set of PCR primers for *adeR* gene was targeting the region between its promoter and the *IS_{Aba125}*

A


ATCC15151



With IS_{Aba125} insertion



With IS_{Aba1} insertion



B

```

-10      ← Pin      -35
GTGCTTAGAAAACAATTATTATGACATTATTTCAATGAGTTATCTATTTTATCGGTGAC
-35      Pout →      -10      IRL
AGGATAATTTTAATGATATGCTCAAAAGCTAGAGGTTTCTGTTAAAAATGCGCAGGTT
M A Q K L E V S V K N A Q V
TGGAAATGCGCCATCGCACATGAGTTAAGAACGCCTATAACGATATTACAAGTCTGTTTA
W N A A I A H E L R T P I T I L Q G R L
CAAGGCATCATCGACGGTGTTTTAAACCTGATGAAGTCTATTAAAAAGCCTTTTAAAT
Q G I I D G V F K P D E V L F K S L L N
CAAGTTGAAGTTTATCTCACTTAGTCGAAGACTTACGGACTTTAAGCTTAGTAGAGAAC
Q V E V L S H L V E D L R T L S L V E N
CAGCAACTCCGGTTAAATTTGAATTTGACTTTAAGCCGGTAGTTGAAAAAGTCTT
Q Q L R L N Y E L F D F K A V V E K V L
AAAGCAATTTGAAGATCGTTTGGATCAAGCTAAGCTAGTACCAGAACTTGACCTAECTTC
K A F E D R L D Q A K L V P E L D L T S
ACTCTGTATATTGCGACCGCGTGTATTGAGCAAGTTTAAATGCTTTAATTGATAAT
T P V Y C D R R R I E Q V L I A L I D N
GCTATACGCTATTCACATGCAGGCAAACTTAAAAATTCCTCGGAAGTGTATCAGAAAAC
A I R Y S H A G K L K I S S E V V S Q N
TGGATATTAATAAATTGAGGATGAAGGCCCGCATTGCAACCGAGTCCAAAGACGATTTA
W I L K I E D E G P G I A T E F Q D D L
TTTAAGCCTTCTTTAGATTAGAAGAAATCAAGGAATAAAGAATTTGCGGCACAGGTTTA
F K P F F R L E E S R N K E F G G T G L
GGTCTGCTGTGTACATGCAATTTGTTGGCACTGAAAGCACTATTCAATATAGCAAT
G L A V V H A I I V A L K G T I Q Y S N
CAAGGCTCGAAAAGTATTTTACCATAAAAAATTTCTATGAATAACTAA
Q G S K S I F T I K I S M N N *
    
```


Figure 3. Alteration of the *adeRS* operons by insertion of *ISAbal25* or *ISAbal1* in multidrug resistant *A. baumannii* isolates. (A) Genetic scheme of wide type *adeRS* operon in ATCC 15151 and two insertion mutations. *ISAbal25* disrupts the *adeR* gene and *ISAbal1* disrupts the *adeS* gene in clinical multidrug resistant *A. baumannii* isolates. Open arrows indicate coding sequences and direction of transcription. *Pade* is the promoter of the *adeABC* operon. Closed arrowheads indicate the position and orientation of the primers used in quantitative *adeR* and *adeS* real-time PCR (all positions are according to accession no. JQ690823-5 in GenBank). IRR, inverted repeat-right; IRL, inverted repeats-left; DR, direct repeat. (B) Presumed promoters in *ISAbal1* and downstream coding sequence of the truncated AdeS. The deduced amino-acid sequence is designated in a single letter code below the nucleotide sequence and the star sign indicates stop codon. The inverted repeat sequences (IRL) of *ISAbal1* are dash-underlined. The -35 and -10 motifs of promoters are indicated as numbers. *Pin* is the promoter for transposase gene in *ISAbal1*, and *Pout* is the promoter for the truncated AdeS derived from *ISAbal1* insertion. The truncated AdeS start codon is boxed.
doi:10.1371/journal.pone.0049534.g003

insertion site in AB392 (Figure 3A). The second set of PCR primers was targeting the terminal region of *adeS* gene after the *ISAbal1* insertion site in AB293 (Figure 3A). We first compared the *adeB* gene expression in TGC resistant isolates (AB096 and AB293) with the proposed basal expression in control strain ATCC 15151. The expression of *adeB* gene increased 622 times and 82 times in AB096 and AB293, respectively. In contrast, only a 42-fold, 1.1-fold and 1.7-fold increase in the *adeB* gene expression was observed in TGC susceptible clinical strains, AB039, AB392 and AB260, respectively. The *adeA* gene showed the same increasing expression pattern in TGC resistant clinical isolates as the *adeB* gene. All the TGC susceptible isolates (ATCC15151, AB260 and AB392) had less transcription of *adeA* and *adeB* consistently. In contrast, the transcription levels of the *adeA* and *adeB* genes in TGC resistant isolates were significantly higher than those in TGC susceptibility isolates (Mann-Whitney Test, *P* value <0.05). We tried to correlate the overexpression of *adeA* and *adeB* genes with their regulatory compartment by quantifying the transcripts of *adeR* and *adeS* genes in the TGC resistant isolates. The level of transcription of *adeR* in AB260 (1.87 ± 0.14) and AB293 (2.45 ± 0.98) was not significantly different (Mann-Whitney Test; *P* value = 0.38). However, the *adeS* gene transcription in AB392 was 12.5-fold lower than in the ATCC 15151 control strain. Lower *adeS* transcription might result from the polar effect after an *ISAbal25* insertion in AB392. The *ISAbal1* insertion also resulted in the same polar effect after an *ISAbal1* insertion in AB260, but did not cause the same polar effect to reduce the *adeS* gene transcription in AB293. Our findings suggested that an extra promoter within the *ISAbal1* element of AB293 constitutively drives the transcription for the remaining *adeS* gene fragment.

A truncated AdeS predicted by DNA sequencing

To determine the structure and function domain of AdeS, we analyzed the full *adeS* gene sequence in ATCC 15151 by the NCBI tool and the transmembrane domain prediction tool. The N-terminus of the AdeS contained two transmembrane segments

(amino acid positions 9–36 and 58–85), which suggests that AdeS is a membrane anchored protein. The C-terminus of AdeS after the second transmembrane segment was the transmitter compartment containing a phosphorylatable HisKA domain and an ATP-binding domain. The insertion site of *ISAbal1* was located between the second transmembrane segment and the transmitter compartment in AB293. Also, a *Pout* promoter overlapping with *Pin* promoter was found near left inverted repeat sequence (IRL) within the *ISAbal1* element (Figure 3B). By analyzing the downstream sequences of the *Pout* promoter, we predicted an ORF encoding a protein with 229 amino acids by ORF finder. The amino acid sequence of the predicted protein was the same as the carboxyl-terminal transmitter domain of AdeS protein. We deduced a truncated AdeS driven by the *Pout* promoter in the *ISAbal1* element (Figure 3B). The predicted protein contained neither transmembrane helices nor a signal peptide. It was suggested to be a truncated protein within the cytoplasm. The truncated AdeS shared 100% amino acid identity with the kinase sensor protein annotated as a hypothetical protein of the MRAB-C strain 1656-2 (GenBank accession number ADX03920). We further analyzed the biological function of the truncated AdeS protein by investigating its possible relationship with two point mutations of AdeR in determining TGC resistance.

Acquired TGC resistance induced by coexistence of the truncated AdeS and mutated AdeR

To further assess the relationship between the truncated AdeS and mutated AdeR in TGC resistant isolates, DNA fragments of the full length *adeRS* operon and the *adeR* gene from different strains (wt, AB260 and AB293) were cloned into the pRS system to construct pRS-*adeRS* (wt, AB260, AB293) and pRS-*adeR* (wt, AB260, AB293), respectively (Figure 4A). The predicted truncated *adeS* operon of AB293 was also cloned into pRS to generate pRS-*Pout*-truncated *adeS*. The pRS-*adeRS* (AB293) was digested with *SphI* and was self-ligated to generate pRS-*Pade*-*Pout*-truncated *adeS*. The *adeRS* operon of ATCC 15151 was destroyed to generate

Table 3. Relationship between tigecycline MICs and expression of *adeRS* and *adeABC* operons in clinical strains of *A. baumannii*.

Strains	Strains	TGC MIC (mg/L)	Differential quantification of gene expression (fold)			
			<i>adeR</i>	<i>adeS</i>	<i>adeA</i>	<i>adeB</i>
Without insertion	ATCC 15151	≤ 0.5	1.00	1.00	1.00	1.00
	AB39	2	1.50 ± 0.73	0.65 ± 0.2	24.15 ± 5.95	42.64 ± 22.49
	AB96	16	1.55 ± 0.15	0.67 ± 0.05	285.75 ± 106.12	622.03 ± 189.32
With insertion	AB392 (<i>ISAbal25</i>)	≤ 0.5	1.21 ± 0.25	0.08 ± 0.02	0.55 ± 0.33	1.05 ± 0.64
	AB260 (<i>ISAbal1</i>)	1	1.87 ± 0.14	2.82 ± 0.88	1.02 ± 0.54	1.71 ± 0.59
	AB293 (<i>ISAbal1</i>)	16	2.45 ± 0.98	2.12 ± 0.35	51.32 ± 9.21	81.75 ± 68.78

doi:10.1371/journal.pone.0049534.t003

a mutant bacterial strain (ABmut02) by homologous recombination with a suicide plasmid. These recombinants and the ABmut02 mutant strain were used to assess the regulation of AdeABC efflux pump expression. The recombinant plasmids were transformed respectively into ATCC 15151 and ABmut02 to obtain the transformed strains. The transformed strains were then tested for their antimicrobial susceptibilities. Results of the antibiotic susceptibility assays were summarized in Table 4. Assays on ATCC15151 wild type strain showed an 8-fold TGC MIC increase after transforming ATCC 15151 with pRS-*adeRS* (AB260), pRS-*adeRS* (AB293), pRS-Pade-Pout-truncated *adeS* or pRS-Pout-truncated *adeS*. The AdeRS-destroyed mutant ABmut02 shared the same TGC MIC with wild type ATCC 15151 after transforming with the pRS-*adeRS* (AB260) or pRS-*adeRS* (AB293). However, contrary to expectation, transformation with pRS-Pade-Pout-truncated-*adeS* or pRS-Pout-truncated-*adeS* did not show higher TGC MIC in ABmut02. We demonstrated that the truncated AdeS must cooperate with AdeR to induce TGC resistance. And the two point mutations in AdeR were proven to have no significant effect on its interaction with the truncated AdeS. To determine whether the multidrug resistance was directly induced by the truncated AdeS in the pRS system, we disrupted the start codon of the truncated AdeS by site directed mutagenesis. We found 16-fold lower TGC MIC and multidrug MIC reduction in ATCC 15151 transformed with the start codon disrupted mutant, pRS-Pout-truncated-*adeS* (SDM). Accordingly, we suggest that truncated AdeS is associated with acquired TGC and multidrug resistance.

Quantifying the *Pade* promoter activity by the β -galactosidase assay

To further differentiate the promoter effect from either *Pade* of *adeABC* operon or *P_{in}* of ISAbal, we quantified *adeA* and *adeB* gene expression in all the transformants listed in Table 4. We constructed a *lacZ* gene reporter system instead of laborious quantification RT-PCR of *adeA* and *adeB*. The *lacZ* gene was cloned as a substitute for the *adeABC* gene in the pRS series (Figure 4B). Then we were able to assay the promoter effect by directly quantifying β -galactosidase activity. The β -galactosidase activities in ATCC 15151 strain with pS01 (13 ± 7 units) and in ABmut02 strain with pS01 (12 ± 6 units) were measured as background. In ATCC 15151, β -galactosidase activities increased about 172-fold (2068 ± 290 units), 149-fold (1783 ± 508 units) and 123-fold after transformation with pRS-*adeRS* (260), pRS-*adeRS* (293), and pRS-Pade-Pout-truncated *adeS*, respectively (Mann-Whitney Test; P value < 0.05). In ABmut02, β -galactosidase activities also increased about 128-fold (1669 ± 766 units) and 135-fold (1757 ± 546 units) after transformation with pRS-*adeRS* (260) and pRS-*adeRS* (293), respectively (Mann-Whitney Test; P value < 0.05) (Figure 5). Transformation of pRS-Pade-Pout-truncated *adeS* can only increase β -galactosidase activity by 20 fold while AdeR is lacking in ABmut02 strain (Mann-Whitney Test; P value < 0.05). The β -galactosidase activity did not increase while being transformed with the recombinant plasmids expressing *adeR* only (wt, 260, 293) into either ATCC 15151 or ABmut02 strains. These results suggested that the expression of the *adeABC* efflux pump was directly controlled by the two-component system, truncated AdeS and AdeR. The expression of β -galactosidase activity was significantly higher in ATCC15151 with pRS-Pade-Pout-truncated *adeS* than with pRS-Pout-truncated *adeS* (Mann-Whitney Test; P value < 0.05). And the lower expression of β -galactosidase activity was observed in ABmut02 with pRS-Pade-Pout-truncated *adeS* than with pRS-Pout-truncated *adeS* (Mann-Whitney Test; P value < 0.05). These results suggested that AdeR protein is necessary for

stimulating *Pade* promoter and enhancing the expression of the *adeABC* efflux pump. In order to rule out the possibility of *P_{in}* promoter of ISAbal on enhancing the expression of *adeABC* operon, we only increased the β -galactosidase activity of ATCC 15151 and ABmut02 transformed with the *P_{in}* containing plasmid pRS-Pout-truncated-*adeS* by 31-fold (374 ± 46 units) and 36-fold (465 ± 48 units), respectively. The β -galactosidase assay successfully quantified the significantly higher *lacZ* activity in the strain transformed with pRS-*adeRS* compared with pRS-Pout-truncated *adeS*. The biological function of truncated *adeS* was further demonstrated besides converting the MIC presentation, and the truncated *adeS* with coexistence of *adeR* can constitutively stimulate the promoter *Pade* to express the *lacZ* gene.

Discussion


Antibiotic resistance is a major challenge in treating infections caused by *A. baumannii* [1]. The *adeABC* operon is located in chromosomal DNA and it endorses the intrinsic low-level expression in *A. baumannii*. [3,7]. The expression of AdeABC efflux pump is tightly regulated by the two-component regulatory system AdeR-AdeS, encoded by the *adeRS* operon that is located upstream of *adeABC* operon and transcribed in the opposite direction [3,7,14]. The overexpression of the AdeABC efflux pump, responsible for reducing accumulation of many antibiotics, is an efficient mechanism for multidrug resistance in *A. baumannii* [43]. AdeS is a membrane-integrated sensor protein with a histidine kinase domain which converts and transfers environmental stimuli to a response regulator AdeR for regulating the AdeABC gene expression [3,7]. On the basis of our current data, we proposed an N-terminal truncated AdeS generated by the Pout promoter within the ISAbal insertion of *adeS* gene. The truncated AdeS protein was able to activate AdeR and then enhance the *adeABC* gene expression.

Ruzin et al. [9] reported they found the disruption of AdeS by the insertion sequence ISAbal in two TGC-resistant isolates of *Acinetobacter calcoaceticus*-*A. baumannii* complex. The AdeABC pumps were overexpressed in these strains and associated with TGC resistant. However, the prevalence, genotype and mechanism of the strain with an ISAbal insertion in *adeS* gene had not been well investigated. In this study, we found 41 of the 317 isolates contained DNA insertions in their *adeRS* operon. Besides the ISAbal insertion of *adeS* gene in 40 isolates as presumed, the remaining one isolate was found with ISAbal25 insertion in its *adeR* gene. Compared with the TGC susceptibility phenotype, we found that 38 of the above 40 isolates accounted for 29.2% (38/130) of the TGC resistant isolates, and they demonstrated differences in the PFGE patterns. This result may indicate a common ancestor shared by these isolates with ISAbal insertion in *adeS* gene.


Previous studies including ours have indicated that the sequence of AdeR and AdeS are widely variable in clinical isolates, but several mutations are still recommended for causing overexpression of the AdeABC efflux pump [10,41,42]. Most of the publications describe point mutations in the sensor domain (Asp30Gly), in the linker domain (Aln94Val) between the recognition domain and the histidine box, and in the histidine box (Tro153Met) of the AdeS [14,44]. A mutation (Pro116Leu) in AdeR is also reported to cause *adeABC* operon overexpression likely due to altering the structural conformation of the regulator [14]. In addition, AdeR mutation (Aln91Val) and AdeS mutation (Gly103Asp) occur concurrently in a susceptibility conversion strain after exposure to TGC. However, the detail interaction among these mutations has not been ascertained [42]. Although

A

ATCC15151



With ISAbal insertion



B

A gene fragment with promoter region




Figure 4. Construction of the pRS recombinant series. (A) Strategies for obtaining a series of DNA fragments containing promoter region of *adeABC* operon and a series of *adeRS* operon variants from wild type (wt) ATCC 15151 and drug resistant strains (260, 293) by PCR. Open arrows denote coding sequences and indicate the direction of transcription in the bacterial genome. The white rectangle box denotes the region of Pade promoter (*Pade* and *Pre*). The red rectangle box denotes the promoter region in *ISAbal1* (*Pin* and *Pout*). Arrows following the rectangle boxes together indicate the PCR fragments used to generate pRS recombinant series. (B) Construction map of the promoter-less *lacZ* gene of pRS system. The pRS system was derived from pS01, which remove *lacI^P-P_{T7}* promoter by engineered *SmaI* and *BamHI* cutting. The pRS system was obtained and used for cloning PCR fragments into upstream of the promoter-less *lacZ* gene of pRS system between *SmaI* and *BamHI* restriction sites. The rectangle box indicates the region of promoters. The region of Pade promoter region contains two overlapped promoters in opposite direction (*Pade* and *Pre*). Two overlapped promoters, *Pin* and *Pout*, were in the region of promoter region in *ISAbal1*. The expression level of *lacZ* gene represented for the activity of promoter of *adeABC* operon or *Pin* promoter of *ISAbal1*.
doi:10.1371/journal.pone.0049534.g004

we found two new mutations (Met197Ile) and (Ser200Cys) on the DNA binding domain of AdeR protein of all TGC resistant strains included in this study, strain AB260 with the same mutations showed lower expression level of the *adeABC* operon and was susceptible to TGC. However, the transformed strains with pRS-*adeRS*(AB293) and with pRS-*adeRS*(AB260) were presented with the presumed higher MIC to TGC. We therefore suggested that the *adeABC* operon expression in the susceptible strain AB260 might be inhibited by some unknown mechanism. Future studies will focus on analyzing the inhibition mechanism of *adeABC* operon expression in the TGC susceptibility strain.

ISAbal1 copies were found in the chromosome and plasmids, which have been known to be related to antibiotic resistance only in *Acinetobacter* spp [27]. Previous genome-wide studies on evaluating the drug resistance mechanism in clinical *A. baumannii* isolates found multidrug resistant isolates carry more *ISAbal1* elements copies (9 to 428) than clinical susceptible strains and laboratory strains [21,45,46,47]. The *ISAbal1* element flanks an

antibiotic resistant gene and is involved in the overexpression of the genes from an outward-facing promoter, *Pout* in the IS element. Another example, disruption of an antibiotics influx pump protein, designated CarO, has also been reported by the *ISAbal1* element insertional inactivation [34]. Other *ISAbal1* insertions are polymorphic and are thus unlikely to be directly related to drug resistance in these strains [48]. Some *ISAbal1* insertion locations are also found in or adjacent to hypothetical protein genes. Previous genome-wide studies have identified an *ISAbal1* insertion in the *adeS* gene and even a presumed sensor kinase protein [21,45]. In this study, a similar *ISAbal1* insertion into *adeS* was demonstrated to generate a truncated AdeS which shared the same amino acid sequence as the predicted sensor kinase protein of the genome-wide study [45]. We therefore suggested that the *A. baumannii* strain with a truncated *adeS* gene through *ISAbal1* insertion may have a worldwide distribution and require further investigation.

Table 4. Antimicrobial susceptibilities of the various *A. baumannii* transformants.

Strains	with plasmid	MIC (mg/liter) of				
		TGC	TGC+ NMP	FEP	CIP	LEV
ATCC 15151 (wt <i>adeRS</i>)	no plasmid	0.25	0.25	2	≤0.25	≤0.12
	pS01	0.125	0.0625	2	≤0.25	≤0.12
	pRS- <i>adeRS</i> (wt)	0.25	0.125	2	≤0.25	≤0.12
	pRS- <i>adeRS</i> (AB260)	2	0.25	16	1	0.25
	pRS- <i>adeRS</i> (AB293)	2	0.25	16	1	0.25
	pRS- <i>adeR</i> (wt)	0.25	0.125	2	≤0.25	≤0.12
	pRS- <i>adeR</i> (AB260)	0.25	0.125	2	≤0.25	≤0.12
	pRS- <i>adeR</i> (AB293)	0.25	0.125	2	≤0.25	≤0.12
	pRS-Pade-Pout-truncated <i>adeS</i>	2	0.25	16	0.5	0.25
	pRS-Pout-truncated <i>adeS</i>	2	0.25	16	0.5	0.25
	pRS-Pout-truncated <i>adeS</i> (SDM)	0.25	0.125	2	≤0.25	≤0.12
	ABmut02 (<i>adeRS</i> destruct)	no plasmid	0.25	0.25	2	≤0.25
pS01		0.25	0.25	2	≤0.25	≤0.12
pRS- <i>adeRS</i> (wt)		0.125	0.0625	2	≤0.25	≤0.12
pRS- <i>adeRS</i> (AB260)		2	0.25	16	0.5	0.25
pRS- <i>adeRS</i> (AB293)		2	0.25	32	1	0.25
pRS- <i>adeR</i> (wt)		0.125	0.0625	2	≤0.25	≤0.12
pRS- <i>adeR</i> (AB260)		0.125	0.0625	2	≤0.25	≤0.12
pRS- <i>adeR</i> (AB293)		0.125	0.0625	2	≤0.25	≤0.12
pRS-Pade-Pout-truncated <i>adeS</i>		0.125	0.0625	2	≤0.25	≤0.12
pRS-Pout-truncated <i>adeS</i>		0.125	0.0625	2	≤0.25	≤0.12
pRS-Pout-truncated <i>adeS</i> (SDM)		0.125	0.0625	2	≤0.25	≤0.12

doi:10.1371/journal.pone.0049534.t004




Figure 5. β -galactosidase activities of transformed strains with various pRS recombinants. ATCC 15151 and ABmut02 cells transformed with various pRS recombinants were grown in LB medium at 37°C overnight. The measurement of β -galactosidase activity was repeated at least three times, and the mean values of one representative experiment performed in triplicate are reported (error bars indicate the standard deviation). The measurement of β -galactosidase activity represents for the activity driven by either *Pade* of *adeABC* operon or *Pin* of *ISAbal1*. doi:10.1371/journal.pone.0049534.g005

Instead of laboriously comparing the possible genomic difference among *A. baumannii* strains, we converted the reference strain ATCC 15151 to an AdeRS-knockout laboratory strain, ABmut02. A series of pRS recombinants carrying different *adeRS* fragments and the *lacZ* reporter gene were then able to be analyzed for their regulatory effect in the mutant strain. By directly quantifying the expression of the *lacZ* gene, we can compare the triggering effect of various *adeRS* operons on the *adeABC* promoter. Because *adeR* and *adeS* operon array sequentially after the same promoter, we did not obtain a laboratory strain solely with *adeR* gene disruption. The MIC of TGC can be as high as 16 mg/L for clinical resistant isolates. However, MICs of TGC were only mildly elevated (MIC = 2 mg/L, 8-folds) after transforming the truncated AdeS into ATCC 15151 and its *adeRS*-knockout derivative. The partially resistance-converting result suggests there are other mechanisms affecting the AdeABC efflux system. We presume some inhibitors offset the truncated AdeS effect in ATCC 15151 and AB260, but not in AB293. This inhibitor proposal may explain why isolate AB260 only demonstrates moderate MIC to TGC (1 mg/L) instead of MIC 16 mg/L in AB293. In addition, boosting *adeS* by transforming a plasmid encoded the truncated *adeS* operon into ATCC 15151 did convert its susceptibility to TGC, while the same plasmid alone was unable to overcome the proposed inhibitor in ATCC 15151 mutant (ABmut02) with the destructed *adeRS*. The observed alteration of MIC to TGC for those artificial transformants supports our proposal indirectly. However, we need more direct evidence to prove this proposal. Moreover, an extraordinary

efflux pump or other resistance mechanism may coexist to result in the aberrantly high MIC to TGC in AB293.

In this report, we have shown the distribution of multidrug resistant *A. baumannii* with the *ISAbal1* insertion in *adeS* gene in Taiwan. We have also demonstrated the existence of a truncated AdeS and its biological function. The truncated AdeS is able to induce multidrug resistance by constitutively stimulating the expression of AdeABC efflux pump through motivating the AdeR to interact with and activate the *adeABC* promoter. Our findings not only confirm the previously presumed additional *adeS* gene after *ISAbal1* insertion, but also further characterize it as another mechanism for *ISAbal1*-related antibiotic resistance. As the two-component system is a vital structure of the bacteria and is used to adapt to changing environmental conditions, insight and applications resulting from studies on *A. baumannii* will probably be broadly applicable to other bacteria.

Acknowledgments

We thank Luis Actis for providing plasmid pMU125. We are grateful to Yoshiaki Kawamura for providing plasmid pYM102.

Author Contributions

Conceived and designed the experiments: JRS TSC. Performed the experiments: JRS YM CMS TSC. Analyzed the data: JRS TYC TSC. Contributed reagents/materials/analysis tools: WYW MCC JCL. Wrote the paper: JRS CLP TSC.

References

1. Peleg AY, Seifert H, Paterson DL (2008) *Acinetobacter baumannii*: emergence of a successful pathogen. *Clin Microbiol Rev* 21: 538–582.
2. Dijkshoorn L, Nemec A, Seifert H (2007) An increasing threat in hospitals: multidrug-resistant *Acinetobacter baumannii*. *Nat Rev Microbiol* 5: 939–951.

3. Coyne S, Courvalin P, Perichon B (2011) Efflux-mediated antibiotic resistance in *Acinetobacter* spp. *Antimicrob Agents Chemother* 55: 947–953.
4. Gordon NC, Wareham DW (2009) A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant *Acinetobacter baumannii* with tigecycline. *J Antimicrob Chemother* 63: 775–780.
5. Cortez-Cordova J, Kumar A (2011) Activity of the efflux pump inhibitor phenylalanine-arginine beta-naphthylamide against the AdeFGH pump of *Acinetobacter baumannii*. *Int J Antimicrob Agents* 37: 420–424.
6. Yahav D, Lador A, Paul M, Leibovici L (2011) Efficacy and safety of tigecycline: a systematic review and meta-analysis. *J Antimicrob Chemother* 66: 1963–1971.
7. Wiecek P, Sacha P, Hauschild T, Zorawski M, Krawczyk M, et al. (2008) Multidrug resistant *Acinetobacter baumannii*—the role of AdeABC (RND family) efflux pump in resistance to antibiotics. *Folia Histochem Cytobiol* 46: 257–267.
8. Vila J, Marti S, Sanchez-Cespedes J (2007) Porins, efflux pumps and multidrug resistance in *Acinetobacter baumannii*. *J Antimicrob Chemother* 59: 1210–1215.
9. Ruzin A, Keeney D, Bradford PA (2007) AdeABC multidrug efflux pump is associated with decreased susceptibility to tigecycline in *Acinetobacter calcoaceticus*-*Acinetobacter baumannii* complex. *J Antimicrob Chemother* 59: 1001–1004.
10. Sun JR, Chan MC, Chang TY, Wang WY, Chiueh TS (2010) Overexpression of the *adeB* gene in clinical isolates of tigecycline-nonsusceptible *Acinetobacter baumannii* without insertion mutations in *adeRS*. *Antimicrob Agents Chemother* 54: 4934–4938.
11. Ruzin A, Immermann FW, Bradford PA (2010) RT-PCR and statistical analyses of *adeABC* expression in clinical isolates of *Acinetobacter calcoaceticus*-*Acinetobacter baumannii* complex. *Microb Drug Resist* 16: 87–89.
12. Damier-Piolle L, Magnet S, Bremont S, Lambert T, Courvalin P (2008) AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 52: 557–562.
13. Coyne S, Rosenfeld N, Lambert T, Courvalin P, Perichon B (2010) Overexpression of resistance-nodulation-cell division pump AdeFGH confers multidrug resistance in *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 54: 4389–4393.
14. Marchand I, Damier-Piolle L, Courvalin P, Lambert T (2004) Expression of the RND-type efflux pump AdeABC in *Acinetobacter baumannii* is regulated by the AdeRS two-component system. *Antimicrob Agents Chemother* 48: 3298–3304.
15. Szurmant H, White RA, Hoch JA (2007) Sensor complexes regulating two-component signal transduction. *Curr Opin Struct Biol* 17: 706–715.
16. Cheung J, Hendrickson WA (2010) Sensor domains of two-component regulatory systems. *Curr Opin Microbiol* 13: 116–123.
17. Essen LO, Mailliet J, Hughes J (2008) The structure of a complete phytochrome sensory module in the Pr ground state. *Proc Natl Acad Sci U S A* 105: 14709–14714.
18. Yang X, Kuk J, Moffat K (2008) Crystal structure of *Pseudomonas aeruginosa* bacteriophytochrome: photoconversion and signal transduction. *Proc Natl Acad Sci U S A* 105: 14715–14720.
19. Mern DS, Ha SW, Khodaverdi V, Gliese N, Gorisch H (2010) A complex regulatory network controls aerobic ethanol oxidation in *Pseudomonas aeruginosa*: indication of four levels of sensor kinases and response regulators. *Microbiology* 156: 1505–1516.
20. Gorisch H (2003) The ethanol oxidation system and its regulation in *Pseudomonas aeruginosa*. *Biochim Biophys Acta* 1647: 98–102.
21. Adams MD, Chan ER, Molyneux ND, Bonomo RA (2010) Genomewide analysis of divergence of antibiotic resistance determinants in closely related isolates of *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 54: 3569–3577.
22. Poirel L, Nordmann P (2006) Carbapenem resistance in *Acinetobacter baumannii*: mechanisms and epidemiology. *Clin Microbiol Infect* 12: 826–836.
23. Hu WS, Yao SM, Fung CP, Hsieh YP, Liu CP, et al. (2007) An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 51: 3844–3852.
24. Corvec S, Caroff N, Espaze E, Giraudeau C, Drugeon H, et al. (2003) AmpC cephalosporinase hyperproduction in *Acinetobacter baumannii* clinical strains. *J Antimicrob Chemother* 52: 629–635.
25. Turton JF, Ward ME, Woodford N, Kaufmann ME, Pike R, et al. (2006) The role of ISAbal in expression of OXA carbapenemase genes in *Acinetobacter baumannii*. *FEMS Microbiol Lett* 258: 72–77.
26. Segal H, Nelson EC, Elisha BG (2004) Genetic environment and transcription of *ampC* in an *Acinetobacter baumannii* clinical isolate. *Antimicrob Agents Chemother* 48: 612–614.
27. Segal H, Garmy S, Elisha BG (2005) Is IS(ABA-1) customized for *Acinetobacter*? *FEMS Microbiol Lett* 243: 425–429.
28. Segal H, Jacobson RK, Garmy S, Bamford CM, Elisha BG (2007) Extended –10 promoter in ISAbal-1 upstream of *blaOXA-23* from *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 51: 3040–3041.
29. Zhou H, Pi BR, Yang Q, Yu YS, Chen YG, et al. (2007) Dissemination of imipenem-resistant *Acinetobacter baumannii* strains carrying the ISAbal *blaOXA-23* genes in a Chinese hospital. *J Med Microbiol* 56: 1076–1080.
30. Lee Y, Kim CK, Lee H, Jeong SH, Yong D, et al. (2011) A novel insertion sequence, ISAbal0, inserted into ISAbal1 adjacent to the *blaOXA-23* gene and disrupting the outer membrane protein gene *carO* in *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 55: 361–363.
31. Chen TL, Wu RC, Shaio MF, Fung CP, Cho WL (2008) Acquisition of a plasmid-borne *blaOXA-58* gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 52: 2573–2580.
32. Poirel L, Figueiredo S, Cattoir V, Carattoli A, Nordmann P (2008) *Acinetobacter* radioresistens as a silent source of carbapenem resistance for *Acinetobacter* spp. *Antimicrob Agents Chemother* 52: 1252–1256.
33. Poirel L, Nordmann P (2006) Genetic structures at the origin of acquisition and expression of the carbapenem-hydrolyzing oxacillinase gene *blaOXA-58* in *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 50: 1442–1448.
34. Mussi MA, Limansky AS, Viale AM (2005) Acquisition of resistance to carbapenems in multidrug-resistant clinical strains of *Acinetobacter baumannii*: natural insertional inactivation of a gene encoding a member of a novel family of beta-barrel outer membrane proteins. *Antimicrob Agents Chemother* 49: 1432–1440.
35. Syn CK, Swarup S (2000) A scalable protocol for the isolation of large-sized genomic DNA within an hour from several bacteria. *Anal Biochem* 278: 86–90.
36. Aranda J, Poza M, Pardo BG, Rumbo S, Rumbo C, et al. (2010) A rapid and simple method for constructing stable mutants of *Acinetobacter baumannii*. *BMC Microbiol* 10: 279.
37. Dorsey CW, Tomaras AP, Actis LA (2002) Genetic and phenotypic analysis of *Acinetobacter baumannii* insertion derivatives generated with a transposome system. *Appl Environ Microbiol* 68: 6353–6360.
38. Zheng L, Baumann U, Reymond JL (2004) An efficient one-step site-directed and site-saturation mutagenesis protocol. *Nucleic Acids Res* 32: e115.
39. Seifert H, Dolzani L, Bressan R, van der Reijden T, van Strijen B, et al. (2005) Standardization and interlaboratory reproducibility assessment of pulsed-field gel electrophoresis-generated fingerprints of *Acinetobacter baumannii*. *J Clin Microbiol* 43: 4328–4335.
40. Morita Y, Narita S, Tomida J, Tokuda H, Kawamura Y (2010) Application of an inducible system to engineer unmarked conditional mutants of essential genes of *Pseudomonas aeruginosa*. *J Microbiol Methods* 82: 205–213.
41. Peleg AY, Adams J, Paterson DL (2007) Tigecycline Efflux as a Mechanism for Nonsusceptibility in *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 51: 2065–2069.
42. Hornsey M, Ellington MJ, Doumith M, Thomas CP, Gordon NC, et al. (2010) AdeABC-mediated efflux and tigecycline MICs for epidemic clones of *Acinetobacter baumannii*. *J Antimicrob Chemother* 65: 1589–1593.
43. Magnet S, Courvalin P, Lambert T (2001) Resistance-nodulation-cell division-type efflux pump involved in aminoglycoside resistance in *Acinetobacter baumannii* strain BM4454. *Antimicrob Agents Chemother* 45: 3375–3380.
44. Coyne S, Guigon G, Courvalin P, Perichon B (2010) Screening and quantification of the expression of antibiotic resistance genes in *Acinetobacter baumannii* with a microarray. *Antimicrob Agents Chemother* 54: 333–340.
45. Park JY, Kim S, Kim SM, Cha SH, Lim SK, et al. (2011) Complete genome sequence of multidrug-resistant *Acinetobacter baumannii* strain 1656-2, which forms sturdy biofilm. *J Bacteriol* 193: 6393–6394.
46. Adams MD, Goglin K, Molyneux N, Hujer KM, Lavender H, et al. (2008) Comparative genome sequence analysis of multidrug-resistant *Acinetobacter baumannii*. *J Bacteriol* 190: 8053–8064.
47. Vallenet D, Nordmann P, Barbe V, Poirel L, Mangelot S, et al. (2008) Comparative analysis of *Acinetobacter* spp.: three genomes for three lifestyles. *PLoS One* 3: e1805.
48. Murat D, Bance P, Callebaut I, Dassa E (2006) ATP hydrolysis is essential for the function of the Uup ATP-binding cassette ATPase in precise excision of transposons. *J Biol Chem* 281: 6850–6859.